“I heard early in the year at the Miami Breast Conference what letrozole was doing with their strategy. We should have changed our strategy with our core messages earlier in regards to selling against letrozole”.

However,

1) Anastrozole prescribing information has no mention of letrozole.
http://www.astrazeneca-us.com/pi/arimidex.pdf

2) Anastrozole’s ‘core messages’ by AZ are against tamoxifen, not letrozole.

3) There are no AZ approved selling pieces against letrozole.

4) Any comparison to a competitor is against AZ company policy without approved material and training.

5) Any oral statements made by AZ reps that minimize anastrozole side effects, ie cardiovascular death rates compared to letrozole, would be considered “misbranding” and put AZ at risk.